An atypical case of Epstein-Barr virus-positive plasma cell post-transplant lymphoproliferative disorder successfully treated with adoptive cell therapy

Br J Haematol. 2021 Oct;195(1):140-143. doi: 10.1111/bjh.17633. Epub 2021 Jun 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Blood Viscosity
  • Clone Cells / chemistry
  • Clone Cells / virology
  • Combined Modality Therapy
  • Epstein-Barr Virus Infections / therapy*
  • Female
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Herpesvirus 4, Human / immunology
  • Herpesvirus 4, Human / isolation & purification
  • Humans
  • Immunocompromised Host
  • Immunoglobulin M / blood
  • Immunosuppressive Agents / adverse effects
  • Immunotherapy, Adoptive*
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / therapy*
  • Lymphoproliferative Disorders / virology
  • Neoplastic Stem Cells / chemistry
  • Neoplastic Stem Cells / virology
  • Paraproteinemias / etiology
  • Paraproteinemias / therapy*
  • Paraproteinemias / virology
  • Paraproteins / analysis
  • Plasma Cells / chemistry
  • Plasma Cells / virology
  • Plasmapheresis
  • Postoperative Complications / therapy*
  • Remission Induction
  • T-Cell Antigen Receptor Specificity
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / transplantation*
  • Transplantation Conditioning / adverse effects
  • Viremia / etiology
  • Viremia / therapy*
  • Virus Activation
  • Young Adult

Substances

  • Immunoglobulin M
  • Immunosuppressive Agents
  • Paraproteins